News
PBM
5.16
-7.36%
-0.41
Weekly Report: what happened at PBM last week (0504-0508)?
Weekly Report · 2d ago
Weekly Report: what happened at PBM last week (0427-0501)?
Weekly Report · 05/04 10:28
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 05/01 12:05
Weekly Report: what happened at PBM last week (0420-0424)?
Weekly Report · 04/27 10:31
Psyence BioMed begins Phase IIb dosing of NPX-5 in adjustment disorder trial
PUBT · 04/24 06:37
Psyence amends amalgamation agreement with GoldCoast Resource Corp
PUBT · 04/24 06:05
Psyence BioMed Begins Phase IIb Dosing of Psilocybin Candidate NPX-5 in Australian Cancer Adjustment Disorder Trial
TipRanks · 04/23 21:13
Psyence BioMed doses first patient in Phase IIb NPX-5 adjustment disorder trial
PUBT · 04/23 11:09
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 04/22 17:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 04/22 12:05
Why Is Psyence Biomedical Stock Falling Wednesday?
Benzinga · 04/22 11:04
3 Penny Stocks to Watch Now, 4/21/26
TipRanks · 04/21 17:19
Why Is Psyence Biomedical Stock Trading Lower On Tuesday?
Benzinga · 04/21 16:54
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 04/20 21:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 04/20 17:05
Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
TipRanks · 04/20 15:59
Save This Psychedelic Stock Watchlist After Trump’s Latest Executive Order
Barchart · 04/20 15:39
PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story
Benzinga · 04/20 14:33
PBM, CMPS, ATAI: Psychedelic Biotech Stocks Soar after White House Order for Faster FDA Reviews
TipRanks · 04/20 14:24
Psyence Biomedical Adds Intraday Equity Purchase Option in White Lion Financing Deal
TipRanks · 04/20 12:49
More
Webull provides a variety of real-time PBM stock news. You can receive the latest news about Psyence Biomedical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.